S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$26.88
+0.55 (+2.09%)
(As of 12/5/2023 ET)
Compare
Today's Range
$26.10
$26.95
50-Day Range
$23.37
$28.68
52-Week Range
$22.01
$33.71
Volume
3.07 million shs
Average Volume
1.60 million shs
Market Capitalization
$4.49 billion
P/E Ratio
21.68
Dividend Yield
N/A
Price Target
$32.29

Alkermes MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
20.1% Upside
$32.29 Price Target
Short Interest
Healthy
4.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
59.26%
From $1.08 to $1.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

62nd out of 948 stocks

Pharmaceutical Preparations Industry

14th out of 421 stocks


ALKS stock logo

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

ALKS Stock News Headlines

Alkermes (NASDAQ:ALKS) Lifted to "Strong-Buy" at StockNews.com
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Alkermes Completes Separation of Oncology Business
Amgen (AMGN) Earnings Watch: Buy or Sell?
Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/25/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,280
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$32.29
High Stock Price Target
$35.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+20.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-158,270,000.00
Pretax Margin
13.68%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$0.28 per share
Book Value
$6.35 per share

Miscellaneous

Free Float
158,937,000
Market Cap
$4.49 billion
Optionable
Optionable
Beta
0.64

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price objectives for Alkermes' shares. Their ALKS share price targets range from $28.00 to $35.00. On average, they anticipate the company's stock price to reach $32.29 in the next year. This suggests a possible upside of 20.1% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2023?

Alkermes' stock was trading at $26.13 at the start of the year. Since then, ALKS stock has increased by 2.9% and is now trading at $26.88.
View the best growth stocks for 2023 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) released its earnings results on Wednesday, October, 25th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.19. The company earned $380.94 million during the quarter, compared to analysts' expectations of $366.18 million. Alkermes had a trailing twelve-month return on equity of 11.41% and a net margin of 13.50%.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY23 earnings guidance on Wednesday, November, 15th. The company provided earnings per share guidance of $1.57-$1.75 for the period, compared to the consensus EPS estimate of $1.58.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.04%), Hardman Johnston Global Advisors LLC (3.37%), Primecap Management Co. CA (2.33%), Bank of New York Mellon Corp (1.66%), Charles Schwab Investment Management Inc. (1.30%) and Morgan Stanley (1.21%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
This page (NASDAQ:ALKS) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -